1rkh › Citations

Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide.

Vanhooke JL, Benning MM, Bauer CB, Pike JW, DeLuca HF
Biochemistry 43 4101-10 (2004)
Related entries: 1rjk, 1rk3, 1rkg

Cited: 95 times
EuropePMC logo PMID: 15065852

Abstract

We have determined the crystal structures of the ligand binding domain (LBD) of the rat vitamin D receptor in ternary complexes with a synthetic LXXLL-containing peptide and the following four ligands: 1alpha,25-dihydroxyvitamin D(3); 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD); 1alpha-hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol (2MbisP), and 2alpha-methyl-19-nor-1alpha,25-dihydroxyvitamin D(3) (2AM20R). The conformation of the LBD is identical in each complex. Binding of the 2-carbon-modified analogues does not change the positions of the amino acids in the ligand binding site and has no effect on the interactions in the coactivator binding pocket. The CD ring of the superpotent analogue, 2MD, is tilted within the binding site relative to the other ligands in this study and to (20S)-1alpha,25-dihydroxyvitamin D(3) [Tocchini-Valentini et al. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 5491-5496]. The aliphatic side chain of 2MD follows a different path within the binding site; nevertheless, the 25-hydroxyl group at the end of the chain occupies the same position as that of the natural ligand, and the hydrogen bonds with histidines 301 and 393 are maintained. 2MbisP binds to the receptor despite the absence of the 25-hydroxyl group. A water molecule is observed between His 301 and His 393 in this structure, and it preserves the orientation of the histidines in the binding site. Although the alpha-chair conformer is highly favored in solution for the A ring of 2AM20R, the crystal structures demonstrate that this ring assumes the beta-chair conformation in all cases, and the 1alpha-hydroxyl group is equatorial. The peptide folds as a helix and is anchored through hydrogen bonds to a surface groove formed by helices 3, 4, and 12. Electrostatic and hydrophobic interactions between the peptide and the LBD stabilize the active receptor conformation. This stablization appears necessary for crystal growth.

Reviews - 1rkh mentioned but not cited (1)

  1. Alternative binding sites at the vitamin D receptor and their ligands. Mutchie TR, Yu OB, Di Milo ES, Arnold LA. Mol Cell Endocrinol 485 1-8 (2019)

Articles - 1rkh mentioned but not cited (1)

  1. A multidisciplinary approach disclosing unexplored Aflatoxin B1 roles in severe impairment of vitamin D mechanisms of action. Persico M, Sessa R, Cesaro E, Dini I, Costanzo P, Ritieni A, Fattorusso C, Grosso M. Cell Biol Toxicol 39 1275-1295 (2023)


Reviews citing this publication (19)

  1. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Physiol Rev 96 365-408 (2016)
  2. Vitamin D, disease and therapeutic opportunities. Plum LA, DeLuca HF. Nat Rev Drug Discov 9 941-955 (2010)
  3. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Pike JW, Meyer MB. Endocrinol Metab Clin North Am 39 255-69, table of contents (2010)
  4. Evolution of our understanding of vitamin D. DeLuca HF. Nutr Rev 66 S73-87 (2008)
  5. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Reschly EJ, Krasowski MD. Curr Drug Metab 7 349-365 (2006)
  6. Regulation of target gene expression by the vitamin D receptor - an update on mechanisms. Pike JW, Meyer MB, Bishop KA. Rev Endocr Metab Disord 13 45-55 (2012)
  7. Orphan nuclear receptors adopted by crystallography. Ingraham HA, Redinbo MR. Curr Opin Struct Biol 15 708-715 (2005)
  8. The vitamin D metabolome: An update on analysis and function. Jenkinson C. Cell Biochem Funct 37 408-423 (2019)
  9. Vitamin D and Its Synthetic Analogs. Maestro MA, Molnár F, Carlberg C. J Med Chem 62 6854-6875 (2019)
  10. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Choi M, Makishima M. Expert Opin Ther Pat 19 593-606 (2009)
  11. Vitamin D receptor ligands: the impact of crystal structures. Carlberg C, Molnár F, Mouriño A. Expert Opin Ther Pat 22 417-435 (2012)
  12. Structural considerations of vitamin D signaling. Molnár F. Front Physiol 5 191 (2014)
  13. Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators. Yamada S, Makishima M. Trends Pharmacol Sci 35 324-337 (2014)
  14. Structural aspects of Vitamin D endocrinology. Rochel N, Molnár F. Mol Cell Endocrinol 453 22-35 (2017)
  15. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment. Ono Y. J Steroid Biochem Mol Biol 139 88-97 (2014)
  16. Therapeutic application of vitamin D receptor ligands: an updated patent review. Takada I, Makishima M. Expert Opin Ther Pat 25 1373-1383 (2015)
  17. Triennial Growth Symposium--Vitamin D: bones and beyond. DeLuca HF. J Anim Sci 92 917-929 (2014)
  18. Vitamin D and Its Receptor from a Structural Perspective. Rochel N. Nutrients 14 2847 (2022)
  19. Significance of the Vitamin D Receptor on Crosstalk with Nuclear Receptors and Regulation of Enzymes and Transporters. Noh K, Chow ECY, Quach HP, Groothuis GMM, Tirona RG, Pang KS. AAPS J 24 71 (2022)

Articles citing this publication (74)

  1. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, Zinser G, Valrance M, Aranda A, Moras D, Norman A, Welsh J, Byers SW. Mol Cell 21 799-809 (2006)
  2. 20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Slominski AT, Kim TK, Janjetovic Z, Tuckey RC, Bieniek R, Yue J, Li W, Chen J, Nguyen MN, Tang EK, Miller D, Chen TC, Holick M. Am J Physiol Cell Physiol 300 C526-41 (2011)
  3. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. Lou YR, Molnár F, Peräkylä M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C, Tuohimaa P. J Steroid Biochem Mol Biol 118 162-170 (2010)
  4. Structural analysis of CYP2R1 in complex with vitamin D3. Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park HW. J Mol Biol 380 95-106 (2008)
  5. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Krasowski MD, Ni A, Hagey LR, Ekins S. Mol Cell Endocrinol 334 39-48 (2011)
  6. Functional evolution of the vitamin D and pregnane X receptors. Reschly EJ, Bainy AC, Mattos JJ, Hagey LR, Bahary N, Mada SR, Ou J, Venkataramanan R, Krasowski MD. BMC Evol Biol 7 222 (2007)
  7. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. Jurutka PW, Thompson PD, Whitfield GK, Eichhorst KR, Hall N, Dominguez CE, Hsieh JC, Haussler CA, Haussler MR. J Cell Biochem 94 917-943 (2005)
  8. Evolution of pharmacologic specificity in the pregnane X receptor. Ekins S, Reschly EJ, Hagey LR, Krasowski MD. BMC Evol Biol 8 103 (2008)
  9. Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. Nascimento AS, Dias SM, Nunes FM, Aparício R, Ambrosio AL, Bleicher L, Figueira AC, Santos MA, de Oliveira Neto M, Fischer H, Togashi M, Craievich AF, Garratt RC, Baxter JD, Webb P, Polikarpov I. J Mol Biol 360 586-598 (2006)
  10. Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Krasowski MD, Yasuda K, Hagey LR, Schuetz EG. Nucl Recept 3 2 (2005)
  11. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Pike JW, Meyer MB. Rheum Dis Clin North Am 38 13-27 (2012)
  12. Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Plum LA, Prahl JM, Ma X, Sicinski RR, Gowlugari S, Clagett-Dame M, DeLuca HF. Proc Natl Acad Sci U S A 101 6900-6904 (2004)
  13. Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. Ciesielski F, Rochel N, Moras D. J Steroid Biochem Mol Biol 103 235-242 (2007)
  14. Perspectives on mechanisms of gene regulation by 1,25-dihydroxyvitamin D3 and its receptor. Pike JW, Meyer MB, Watanuki M, Kim S, Zella LA, Fretz JA, Yamazaki M, Shevde NK. J Steroid Biochem Mol Biol 103 389-395 (2007)
  15. Quantification of the vitamin D receptor-coregulator interaction. Teichert A, Arnold LA, Otieno S, Oda Y, Augustinaite I, Geistlinger TR, Kriwacki RW, Guy RK, Bikle DD. Biochemistry 48 1454-1461 (2009)
  16. Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket. Molnár F, Peräkylä M, Carlberg C. J Biol Chem 281 10516-10526 (2006)
  17. Emerging regulatory paradigms for control of gene expression by 1,25-dihydroxyvitamin D3. Pike JW, Meyer MB, Martowicz ML, Bishop KA, Lee SM, Nerenz RD, Goetsch PD. J Steroid Biochem Mol Biol 121 130-135 (2010)
  18. Ligand-specific structural changes in the vitamin D receptor in solution. Singarapu KK, Zhu J, Tonelli M, Rao H, Assadi-Porter FM, Westler WM, DeLuca HF, Markley JL. Biochemistry 50 11025-11033 (2011)
  19. Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA. J Med Chem 55 4640-4651 (2012)
  20. The retinoid X receptor ligand restores defective signalling by the vitamin D receptor. Sánchez-Martínez R, Castillo AI, Steinmeyer A, Aranda A. EMBO Rep 7 1030-1034 (2006)
  21. Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives. Masuno H, Ikura T, Morizono D, Orita I, Yamada S, Shimizu M, Ito N. J Lipid Res 54 2206-2213 (2013)
  22. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. Ke HZ, Qi H, Crawford DT, Simmons HA, Xu G, Li M, Plum L, Clagett-Dame M, DeLuca HF, Thompson DD, Brown TA. J Bone Miner Res 20 1742-1755 (2005)
  23. A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation. Cui J, Ma C, Qiu J, Ma X, Wang X, Chen H, Huang B. Mol Cell Endocrinol 338 84-92 (2011)
  24. Antagonist- and inverse agonist-driven interactions of the vitamin D receptor and the constitutive androstane receptor with corepressor protein. Lempiäinen H, Molnár F, Macias Gonzalez M, Peräkylä M, Carlberg C. Mol Endocrinol 19 2258-2272 (2005)
  25. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Vanhooke JL, Tadi BP, Benning MM, Plum LA, DeLuca HF. Arch Biochem Biophys 460 161-165 (2007)
  26. Structure-based design of a superagonist ligand for the vitamin D nuclear receptor. Hourai S, Rodrigues LC, Antony P, Reina-San-Martin B, Ciesielski F, Magnier BC, Schoonjans K, Mouriño A, Rochel N, Moras D. Chem Biol 15 383-392 (2008)
  27. Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Eelen G, Valle N, Sato Y, Rochel N, Verlinden L, De Clercq P, Moras D, Bouillon R, Muñoz A, Verstuyf A. Chem Biol 15 1029-1034 (2008)
  28. Identification of a highly potent vitamin D receptor antagonist: (25S)-26-adamantyl-25-hydroxy-2-methylene-22,23-didehydro-19,27-dinor-20-epi-vitamin D3 (ADMI3). Igarashi M, Yoshimoto N, Yamamoto K, Shimizu M, Ishizawa M, Makishima M, DeLuca HF, Yamada S. Arch Biochem Biophys 460 240-253 (2007)
  29. Crosslinked Aspartic Acids as Helix-Nucleating Templates. Zhao H, Liu QS, Geng H, Tian Y, Cheng M, Jiang YH, Xie MS, Niu XG, Jiang F, Zhang YO, Lao YZ, Wu YD, Xu NH, Li ZG. Angew Chem Int Ed Engl 55 12088-12093 (2016)
  30. LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators. Mita Y, Dodo K, Noguchi-Yachide T, Miyachi H, Makishima M, Hashimoto Y, Ishikawa M. Bioorg Med Chem Lett 20 1712-1717 (2010)
  31. 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure. Shimizu M, Miyamoto Y, Takaku H, Matsuo M, Nakabayashi M, Masuno H, Udagawa N, DeLuca HF, Ikura T, Ito N. Bioorg Med Chem 16 6949-6964 (2008)
  32. Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone. Hwang JY, Huang W, Arnold LA, Huang R, Attia RR, Connelly M, Wichterman J, Zhu F, Augustinaite I, Austin CP, Inglese J, Johnson RL, Guy RK. J Biol Chem 286 11895-11908 (2011)
  33. Removal of the 20-methyl group from 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD) selectively eliminates bone calcium mobilization activity. Barycki R, Sicinski RR, Plum LA, Grzywacz P, Clagett-Dame M, Deluca HF. Bioorg Med Chem 17 7658-7669 (2009)
  34. The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs. Zella LA, Chang CY, McDonnell DP, Pike JW. Arch Biochem Biophys 460 206-212 (2007)
  35. Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol. Rochel N, Hourai S, Pérez-García X, Rumbo A, Mourino A, Moras D. Arch Biochem Biophys 460 172-176 (2007)
  36. 2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism. Yoshimoto N, Inaba Y, Yamada S, Makishima M, Shimizu M, Yamamoto K. Bioorg Med Chem 16 457-473 (2008)
  37. 2MD, a new anabolic agent for osteoporosis treatment. Plum LA, Fitzpatrick LA, Ma X, Binkley NC, Zella JB, Clagett-Dame M, DeLuca HF. Osteoporos Int 17 704-715 (2006)
  38. Functional diversification of vitamin D receptor paralogs in teleost fish after a whole genome duplication event. Kollitz EM, Hawkins MB, Whitfield GK, Kullman SW. Endocrinology 155 4641-4654 (2014)
  39. Molecular determinants of MED1 interaction with the DNA bound VDR-RXR heterodimer. Belorusova AY, Bourguet M, Hessmann S, Chalhoub S, Kieffer B, Cianférani S, Rochel N. Nucleic Acids Res 48 11199-11213 (2020)
  40. New derivatives of 1alpha,25-dihydroxy-19-norvitamin D3 with two substituents at C-2: synthesis and biological activity. Shimizu M, Iwasaki Y, Shimazaki M, Amano Y, Yamamoto K, Reischl W, Yamada S. Bioorg Med Chem Lett 15 1451-1455 (2005)
  41. Structural basis for vitamin D receptor agonism by novel non-secosteroidal ligands. Asano L, Ito I, Kuwabara N, Waku T, Yanagisawa J, Miyachi H, Shimizu T. FEBS Lett 587 957-963 (2013)
  42. Structural basis of the histidine-mediated vitamin D receptor agonistic and antagonistic mechanisms of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone. Kakuda S, Ishizuka S, Eguchi H, Mizwicki MT, Norman AW, Takimoto-Kamimura M. Acta Crystallogr D Biol Crystallogr 66 918-926 (2010)
  43. Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse. Nieves NJ, Ahrens JM, Plum LA, DeLuca HF, Clagett-Dame M. J Invest Dermatol 130 2359-2367 (2010)
  44. Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro. Taneja G, Chu C, Maturu P, Moorthy B, Ghose R. Drug Metab Dispos 46 397-404 (2018)
  45. NMR assignments of tryptophan residue in apo and holo LBD-rVDR. Sicinska W, Westler WM, DeLuca HF. Proteins 61 461-467 (2005)
  46. Vitamin D machinery and metabolism in porcine adipose-derived mesenchymal stem cells. Valle YL, Almalki SG, Agrawal DK. Stem Cell Res Ther 7 118 (2016)
  47. 2-Methylene-19-nor-1alpha-hydroxyvitamin D3 analogs inhibit adipocyte differentiation and PPARgamma2 gene transcription. Thomson B, Ahrens JM, Ntambi JM, DeLuca HF, Clagett-Dame M. Arch Biochem Biophys 460 192-201 (2007)
  48. Analogs of 1alpha,25-dihydroxyvitamin D3 with high potency in induction of osteoclastogenesis and prevention of dendritic cell differentiation: synthesis and biological evaluation of 2-substituted 19-norvitamin D analogs. Shimazaki M, Miyamoto Y, Yamamoto K, Yamada S, Takami M, Shinki T, Udagawa N, Shimizu M. Bioorg Med Chem 14 4645-4656 (2006)
  49. Synthesis and biological activities of new 1alpha,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain. Shimizu M, Miyamoto Y, Kobayashi E, Shimazaki M, Yamamoto K, Reischl W, Yamada S. Bioorg Med Chem 14 4277-4294 (2006)
  50. Synthesis and biological evaluation of a des-C,D-analog of 2-methylene-19-nor-1alpha,25-(OH)2D3. Plonska-Ocypa K, Grzywacz P, Sicinski RR, Plum LA, DeLuca HF. J Steroid Biochem Mol Biol 103 298-304 (2007)
  51. The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung. Ormerod AK, Xing Z, Pedigo NG, Mishra A, Kaetzel DM. Exp Lung Res 34 155-182 (2008)
  52. 13-Methyl-substituted des-C,D analogs of (20S)-1alpha,25-dihydroxy-2-methylene-19-norvitamin D3 (2MD): synthesis and biological evaluation. Plonska-Ocypa K, Sicinski RR, Plum LA, Grzywacz P, Frelek J, Clagett-Dame M, DeLuca HF. Bioorg Med Chem 17 1747-1763 (2009)
  53. Differential recruitment of coactivators to the vitamin D receptor transcriptional complex by 1alpha,25-dihydroxyvitamin D3 analogs. Schwinn MK, DeLuca HF. Arch Biochem Biophys 465 443-451 (2007)
  54. Local motifs involved in the canonical structure of the ligand-binding domain in the nuclear receptor superfamily. Tsuji M. J Struct Biol 185 355-365 (2014)
  55. Structural development of p-carborane-based potent non-secosteroidal vitamin D analogs. Fujii S, Sekine R, Kano A, Masuno H, Songkram C, Kawachi E, Hirano T, Tanatani A, Kagechika H. Bioorg Med Chem 22 5891-5901 (2014)
  56. 13,13-Dimethyl-des-C,D analogues of (20S)-1α,25-dihydroxy-2-methylene-19-norvitamin D₃ (2MD): total synthesis, docking to the VDR, and biological evaluation. Plonska-Ocypa K, Sibilska I, Sicinski RR, Sicinska W, Plum LA, DeLuca HF. Bioorg Med Chem 19 7205-7220 (2011)
  57. Design and synthesis of tetraol derivatives of 1,12-dicarba-closo-dodecaborane as non-secosteroidal vitamin D analogs. Fujii S, Kano A, Masuno H, Songkram C, Kawachi E, Hirano T, Tanatani A, Kagechika H. Bioorg Med Chem Lett 24 4515-4519 (2014)
  58. Isolation and identification of 2alpha,25-dihydroxyvitamin D3, a new metabolite from Pseudonocardia autotrophica 100U-19 cells incubated with Vitamin D3. Takeda K, Kominato K, Sugita A, Iwasaki Y, Shimazaki M, Shimizu M. Steroids 71 736-744 (2006)
  59. Alanine scanning mutational analysis of the ligand binding pocket of the human Vitamin D receptor. Yamamoto K, Choi M, Abe D, Shimizu M, Yamada S. J Steroid Biochem Mol Biol 103 282-285 (2007)
  60. Letter Regulation of the vitamin D receptor by vitamin D lactam derivatives. Asano L, Waku T, Abe R, Kuwabara N, Ito I, Yanagisawa J, Nagasawa K, Shimizu T. FEBS Lett 590 3270-3279 (2016)
  61. SRC2-3 binds to vitamin D receptor with high sensitivity and strong affinity. Egawa D, Itoh T, Kato A, Kataoka S, Anami Y, Yamamoto K. Bioorg Med Chem 25 568-574 (2017)
  62. Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction. Hwang JY, Attia RR, Carrillo AK, Connelly MC, Guy RK. Bioorg Med Chem Lett 23 1891-1895 (2013)
  63. A human vitamin D receptor mutant activated by cholecalciferol. Ousley AM, Castillo HS, Duraj-Thatte A, Doyle DF, Azizi B. J Steroid Biochem Mol Biol 125 202-210 (2011)
  64. Computational analysis of the active sites in binary and ternary complexes of the vitamin D receptor. Sicinska W, Rotkiewicz P. J Steroid Biochem Mol Biol 103 305-309 (2007)
  65. Structural changes of vitamin D receptor induced by 20-epi-1alpha,25-(OH)2D3: an insight from a computational analysis. Sicinska W, Rotkiewicz P. J Steroid Biochem Mol Biol 113 253-258 (2009)
  66. Synthesis of 19-norcalcitriol analogs with elongated side chain. Brzeminski P, Fabisiak A, Sektas K, Berkowska K, Marcinkowska E, Sicinski RR. J Steroid Biochem Mol Biol 177 231-234 (2018)
  67. Vitamin D receptor enhances NLRC4 inflammasome activation by promoting NAIPs-NLRC4 association. Chen X, Zhang Z, Sun N, Li J, Ma Z, Rao Z, Sun X, Zeng Q, Wu Y, Li J, Zhang J, Chen Y. EMBO Rep 23 e54611 (2022)
  68. D-seco-Vitamin D analogs having reversed configurations at C-13 and C-14: Synthesis, docking studies and biological evaluation. Szybinski M, Sokolowska K, Sicinski RR, Plum LA, DeLuca HF. J Steroid Biochem Mol Biol 173 57-63 (2017)
  69. Differential activity of 2-methylene-19-nor vitamin D analogs on growth factor gene expression in rhino mouse skin and comparison to all-trans retinoic acid. Ahrens JM, Jones JD, Nieves NJ, Mitzey AM, DeLuca HF, Clagett-Dame M. PLoS One 12 e0188887 (2017)
  70. Efficient stable isotope labeling and purification of vitamin D receptor from inclusion bodies. Zhu J, Rao H, Tonelli M, Westler WM, Singarapu KK, Markley JL, DeLuca HF, Assadi-Porter FM. Protein Expr Purif 85 25-31 (2012)
  71. Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists. Yoshihara A, Kawasaki H, Masuno H, Takada K, Numoto N, Ito N, Hirata N, Kanda Y, Ishizawa M, Makishima M, Kagechika H, Tanatani A. Biomolecules 12 130 (2022)
  72. RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression. Quarni W, Lungchukiet P, Tse A, Wang P, Sun Y, Kasiappan R, Wu JY, Zhang X, Bai W. J Steroid Biochem Mol Biol 173 157-167 (2017)
  73. Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs. Li F, Song C, Zhang Y, Wu D. Acta Biochim Biophys Sin (Shanghai) 54 12-24 (2022)
  74. Recombinant Expression, Isotope Labeling and Purification of the Vitamin D Receptor Binding Peptide. Chae YK, Singarapu K, Westler WM, Markley JL. Bull Korean Chem Soc 32 4337-4340 (2011)


Quick links